Head & Neck/Thyroid Cancers
From the Journals
Papillary thyroid microcarcinoma: Is ‘less is more’ the right approach?
Expert questions whether current guidance favoring total thyroidectomy goes too far.
Conference Coverage
Keynote 040: Pembrolizumab misses efficacy endpoint in advanced HNSCC
MADRID – Median OS in the ITT population was 8.4 months in the pembrolizumab arm, vs. 7.1 months in the standard-of-care arm.
From the Journals
Liquid biopsy predicts checkpoint inhibitor response
The overall response rate to immune checkpoint inhibitors was 45% among cancer patients who had more than three variants of unknown significance...
Conference Coverage
Calcitonin-to-CEA ratio predicts medullary thyroid cancer survival
Can a ratio of serum calcitonin to carcinoembryonic antigen predict survival in patients with medullary thyroid cancer?
Conference Coverage
AML risk is doubled in low-risk thyroid cancer patients unnecessarily given radioactive iodine therapy
MADRID - Unnecessary radioactive iodine treatment is associated with nearly twice the risk of developing acute myeloid leukemia (AML) in patients...
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...
Conference Coverage
Big changes coming for thyroid cancer staging
How big an impact will new thyroid staging criteria have on the numbers of stage I disease? It’ll be huge.
Conference Coverage
Contralateral nodal thyroid metastases show slow progression
BOSTON – In some thyroid cancers, a small level III contralateral nodal metastasis may be watched safely rather than resected.
Conference Coverage
Revised thyroid Bethesda System resets malignant risks
BOSTON – Revised thyroid cancer cytology system “limits malignancy to cases with features of classic malignant papillary thyroid carcinoma.”
Conference Coverage
VIDEO: Lenvatinib’s real-world thyroid cancer performance matches trial
The median time of progression-free survival was 10 months in the registry and 18 months in the pivotal trial.
Conference Coverage
Thyroid-nodule size boosts serum thyroglobulin’s diagnostic value
Size does matter – at least when it comes to normalizing the serum thyroglobulin level.